What happens to patients with rheumatoid arthritis? The long-term outcome of treatment

1988 ◽  
Vol 7 (3) ◽  
pp. 315-330 ◽  
Author(s):  
T. D. Spector ◽  
D. L. Scott
Keyword(s):  
Rheumatoid Arthritis ◽  
Term Outcome ◽  
Long Term Outcome

LONG-TERM OUTCOME OF TREATING RHEUMATOID ARTHRITIS: RESULTS AFTER 20 YEARS

The Lancet ◽  
1987 ◽  
Vol 329 (8542) ◽  
pp. 1108-1111 ◽  
Author(s):  
D.L. Scott ◽  
B.L. Coulton ◽  
D.P.M. Symmons ◽  
A.J. Popert
Keyword(s):  
Rheumatoid Arthritis ◽  
Term Outcome ◽  
Long Term Outcome

Long-term outcome of total knee replacement in patients with rheumatoid arthritis

2008 ◽  
Vol 75 (2) ◽  
pp. 163-166 ◽  
Author(s):  
Klemmens Trieb ◽  
Maximillian Schmid ◽  
Thomas Stulnig ◽  
Wolfgang Huber ◽  
Axel Wanivenhaus
Keyword(s):  
Rheumatoid Arthritis ◽  
Total Knee Replacement ◽  
Knee Replacement ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Total Knee

scholarly journals Rheumatoid arthritis patients on persistent moderate disease activity on biologics have adverse 5-year outcome compared to persistent low-remission status and represent a heterogeneous group

2020 ◽  
Vol 22 (1) ◽  
Author(s):  
Irini Genitsaridi ◽  
Irini Flouri ◽  
Dimitris Plexousakis ◽  
Konstantinos Marias ◽  
Kyriaki Boki ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Clinical Practice ◽  
Disease Activity ◽  
Serious Adverse Events ◽  
Term Outcome ◽  
Mixed Effect ◽  
Long Term Outcome ◽  
Moderate Disease ◽  
Moderate Disease Activity

Abstract Background The long-term outcome of rheumatoid arthritis (RA) patients who in clinical practice exhibit persistent moderate disease activity (pMDA) despite treatment with biologics has not been adequately studied. Herein, we analyzed the 5-year outcome of the pMDA group and assessed for within-group heterogeneity. Methods We included longitudinally monitored RA patients from the Hellenic Registry of Biologic Therapies with persistent (cumulative time ≥ 50% of a 5-year period) moderate (pMDA, 3.2 < DAS28 ≤ 5.1) or remission/low (pRLDA, DAS28 ≤ 3.2) disease activity. The former was further classified into persistent lower-moderate (plMDA, DAS28 < 4.2) and higher-moderate (phMDA, DAS28 ≥ 4.2) subgroups. Five-year trajectories of functionality (HAQ) were the primary outcome in comparing pRLDA versus pMDA and assessing heterogeneity within the pMDA subgroups through multivariable mixed-effect regression. We further compared serious adverse events (SAEs) occurrence between the two groups. Results We identified 295 patients with pMDA and 90 patients with pRLDA, the former group comprising of plMDA (n = 133, 45%) and phMDA (n = 162, 55%). pMDA was associated with worse 5-year functionality trajectory than pRLDA (+ 0.27 HAQ units, CI 95% + 0.22 to + 0.33; p < 0.0001), while the phMDA subgroup had worse 5-year functionality than plMDA (+ 0.26 HAQ units, CI 95% 0.18 to 0.36; p < 0.0001). Importantly, higher persistent disease activity was associated with more SAEs [pRLDA: 0.2 ± 0.48 vs pMDA: 0.5 ± 0.96, p = 0.006; plMDA: 0.32 ± 0.6 vs phMDA: 0.64 ± 1.16, p = 0.038]. Male gender (p = 0.017), lower baseline DAS28 (p < 0.001), HAQ improvement > 0.22 (p = 0.029), and lower average DAS28 during the first trimester since treatment initiation (p = 0.001) independently predicted grouping into pRLDA. Conclusions In clinical practice, RA patients with pMDA while on bDMARDs have adverse long-term outcomes compared to lower disease activity status, while heterogeneity exists within the pMDA group in terms of 5-year functionality and SAEs. Targeted studies to better characterize pMDA subgroups are needed, in order to assist clinicians in tailoring treatments.

scholarly journals The relation between cartilage biomarkers (C2C, C1,2C, CS846, and CPII) and the long-term outcome of rheumatoid arthritis patients within the CAMERA trial

2011 ◽  
Vol 13 (3) ◽  
pp. R70 ◽  
Author(s):  
Marije F Bakker ◽  
Suzanne MM Verstappen ◽  
Paco MJ Welsing ◽  
Johannes WG Jacobs ◽  
Zalima N Jahangier ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Cartilage Biomarkers

OP0183 Long-Term Outcome of Rheumatoid Arthritis Defined According to the 2010-Classification Criteria

2013 ◽  
Vol 72 (Suppl 3) ◽  
pp. A114.4-A115
Author(s):  
J. A. B. Van Nies ◽  
L. E. Burgers ◽  
L. Y. Ho ◽  
D. P. C. de Rooy ◽  
T. W. J. Huizinga ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Classification Criteria ◽  
Term Outcome ◽  
Long Term Outcome

scholarly journals Long-term outcome in rheumatoid arthritis: A simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year followup

2002 ◽  
Vol 47 (4) ◽  
pp. 383-390 ◽  
Author(s):  
K. W. Drossaers-Bakker ◽  
A. H. Zwinderman ◽  
T. P. M. Vliet Vlieland ◽  
D. Van Zeben ◽  
K. Vos ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Simple Algorithm ◽  
Disease Course ◽  
Term Outcome ◽  
Radiographic Damage ◽  
Long Term Outcome

scholarly journals Long-term outcome of total lymphoid irradiation in rheumatoid arthritis: Comment on the article by Westhovens et al

1998 ◽  
Vol 41 (5) ◽  
pp. 945-946 ◽  
Author(s):  
R. Blanco ◽  
S. S�nchez-Andrada ◽  
V. Mart�nez-Taboada ◽  
J. L. Pe�a Sagredo ◽  
V. Rodr�guez-Valverde
Keyword(s):  
Rheumatoid Arthritis ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Total Lymphoid Irradiation
Sign in / Sign up

Export Citation Format

Share Document